Company news

Zevra Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates

August 10, 2022

KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications

August 8, 2022

KemPharm to Report Second Quarter 2022 Financial Results

August 3, 2022

KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference

August 1, 2022

KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting

July 25, 2022

KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion

May 31, 2022

KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline

May 14, 2022

KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates

May 11, 2022

KemPharm to Present at Multiple Upcoming Investor Conferences

May 10, 2022

KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)

May 4, 2022

KemPharm to Report First Quarter 2022 Financial Results

May 3, 2022

KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

April 18, 2022

KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates

March 29, 2022

KemPharm to Participate in Maxim’s 2022 Virtual Growth Conference

March 23, 2022

KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial

March 20, 2022

KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)

March 15, 2022

KemPharm to Report Fourth Quarter and Full-Year 2021 Results

March 9, 2022

KemPharm Completes KP1077 Pre-IND Meeting Process with FDA

February 22, 2022

KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy

January 18, 2022

KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion

January 11, 2022

KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference

January 10, 2022

KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022”

January 5, 2022

KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program

December 19, 2021

KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX”

December 13, 2021

KemPharm to be Added to the Nasdaq Biotechnology Index Effective December 20, 2021

December 12, 2021

KemPharm Named 2021 David J. Gury Company of the Year by BioFlorida

December 12, 2021

KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates

November 9, 2021

KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD

November 4, 2021

KemPharm to Report Third Quarter 2021 Results

November 2, 2021

AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress

October 26, 2021

KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at Multiple Medical Conferences during ADHD Awareness Month (October)

October 19, 2021

KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market

October 18, 2021

KemPharm to Present at the Benzinga Healthcare Small Cap Conference

September 26, 2021

KemPharm to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

September 22, 2021

KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

September 8, 2021

KemPharm Appoints Tamara A. Seymour to Board of Directors

August 17, 2021

KemPharm Reports Second Quarter 2021 Financial Results

August 11, 2021

KemPharm to Report Second Quarter 2021 Results

August 4, 2021

KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.

July 20, 2021

KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement

June 17, 2021

KemPharm to be Added to Russell 2000® and Russell 3000® Indexes Effective June 28, 2021

June 8, 2021

KemPharm Executives to Participate in Panel Discussions During Upcoming June 2021 Conferences

June 2, 2021

KemPharm, Inc. Announces Orange Book Listing for Six Patents Covering Serdexmethylphenidate (SDX) and Confirmation of NCE Status

May 25, 2021

KemPharm Reports First Quarter 2021 Financial Results

May 12, 2021

KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified as a Schedule IV Controlled Substance by the DEA

May 6, 2021

KemPharm to Report First Quarter 2021 Results

May 5, 2021

KemPharm Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS™ Per License Agreement with Affiliate of Gurnet Point Capital

April 20, 2021

KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™

April 7, 2021

KemPharm Reports Fourth Quarter and Full-Year 2020 Financial Results

March 10, 2021

KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results

March 8, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 12 calls. Every call is listed under its year.

Decks

The 5 newest of 61 decks. Every deck is listed under its year.